Founded in 1999, BD Venture Limited is a venture capital arm of Becton, Dickinson and Company (BD), specialising in investments in early and late stage ventures.

The firm primarily invests in the medical technology, life science, and biotechnology sectors with a focus on drug and vaccine delivery technologies; infectious disease diagnostics and monitoring; cancer diagnostics and monitoring; diabetes and other auto-immune diseases monitoring and treatment; cell-based therapies and tissue engineering; and cell biology research products areas.

The firm prefers to invest in North America, Europe and Bangladesh. It typically invests between $500,000 and $5 million. The firm seeks to lead or co-invest with private and corporate venture capital funds in its portfolio companies. It prefers to make investments in companies that match the strategic interests of its parent organization.

Notable investments include: RenaMed Biologics (R&D of kidney treatments) and ViaCyte (preclinical therapeutic company focused on a product which can free type-1 and 2 diabetes patients from insulin dependence).